US Patent Issued to Gulch Pharma on July 7 for "Oral formulation comprising a crystalline form of rabeximod" (Swedish Inventor)

ALEXANDRIA, Va., July 7 -- United States Patent no. 12,673,056, issued on July 7, was assigned to Gulch Pharma AB (Sollentuna, Sweden).

"Oral formulation comprising a crystalline form of rabeximod" was invented by Ulf Bjorklund (Uppsala, Sweden).

According to the abstract* released by the U.S. Patent & Trademark Office: "The present invention relates to a solid oral composition comprising a crystalline form of Rabeximod or a pharmaceutically acceptable salt thereof and optionally a pharmaceutically acceptable additive."

The patent was filed on June 10, 2021, under Application No. 18/000,945.

*For further information, including images, charts and tables, please visit: http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&...